- Home
- SHMD vs AVIR Comparison
SHMD vs AVIR Comparison
Compare SHMD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHMD | AVIR |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | Germany | United States |
| Employees | 734 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.1M | 399.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SHMD | AVIR |
|---|---|---|
| Price | $4.22 | $4.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 848.5K | 365.4K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $2.78 |
| 52 Week High | $10.65 | $6.45 |
Technical Indicators
Market Signals| Indicator | SHMD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 55.20 |
| Support Level | $3.82 | $4.14 |
| Resistance Level | $4.69 | $5.04 |
| Average True Range (ATR) | 0.49 | 0.23 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 9.17 | 72.52 |
Price Performance
Historical ComparisonAbout SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.